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Blake Drains as chest tubes in lung resection patients
Nitadori, Jun-Ichi; Yoshida, Junji; Nishimura, Mituyo; Nagai, Kanji 
Thoracic Oncology Division, National Cancer Center Hospital East, 
Chiba-Ken, Japan
Background: In Japan, an increasing number of surgeons use a Blake 
Drain (Ethicon, Somerville, NJ) as a chest tube after lung resection to 
reduce the removal workload. However, optimum Blake Drain length 
and placement has not been established, nor removal wound closure 
method. We started using Blake Drains in August 2002 in place of 
traditional chest tubes after lung resection.
Objective: Evaluate use of a single 19 Fr Blake Drain in place of a 
single 28/32 Fr chest tube after lung resection. Compare two Blake 
Drain lengths and placement. Evaluate Blake Drain removal without 
tube wound suturing.
Methods: At the National Cancer Center Hospital East, from August 
2002 through December 2006, we used a single 19 Fr Blake Drain for 
chest cavity drainage in 450 consecutive patients undergoing lung re-
section. Initially, until August 2004, the Blake Drain was inserted at the 
7th intercostal space, up along the vertebrae, to the chest cavity apex 
(short type: ST). From September 2004, a longer Blake Drain was used, 
running to the apex and then turning down the front chest wall, almost 
reaching the diaphragm (long type: LT). 
Results: There were 273 men and 177 women. Of them, 396 patients 
underwent lung resection for primary lung cancer, 37 for metastatic 
cancer, and 17 for various benign diseases. Three patients underwent 
bilateral thoracotomy, and 453 Blake Drains were placed. Length dis-
tribution was almost evenly split with 222 ST and 231 LT Blake Drains 
placed. Three hundred and thirty-six patients underwent lobectomy 
(ST: 171, LT: 165), 20 bilobectomy (ST: 7, LT: 13), 19 pneumonectomy 
(ST: 9, LT: 10), 7 segmentectomy (ST: 3, LT: 4), 67 wedge resection 
(ST: 19, LT: 48), and 4 exploratory thoracotomy (ST: 3, LT: 1).
The Blake Drains were removed an average of 4 (range 1-21) days after 
surgery. We had the, not unusual, complications of tube obstruction or 
massive subcutaneous emphysema due to poor air drainage, but nothing 
unique to the Blake Drain. Tube obstruction occurred in 37 (16.7%) ST 
patients and in 3 (1.3%) LT patients (p<0.001). We replaced the Blake 
Drain with trocar tubes due to obstruction or massive subcutaneous 
emphysema in 5 (2.3%) ST patients and 4 (1.7%) LT patients (p=0.69). 
The Blake Drain removal wounds were sutured in 59 (26.6%) ST 
patients and 14 (6.1%) LT patients (p<0.001). 
Summary: Tube obstruction occurred signiﬁcantly more frequently 
in ST patients. However, there was no difference in the need for Blake 
Drain replacement between ST and LT patients. Initially we were not 
conﬁdent in using just tape and leaving the removal wound un-sutured 
so more ST patients had removal wound suturing. Less than 10% of the 
LT patients needed suturing. This occurred mostly if the Blake Drain 
was in for a long period.
Conclusions: Blake Drains in the Long Tube placement showed good 
drainage capability in lung resection patients. Most patients did not 
need Blake Drain removal wound suturing. This saves considerable 
surgeon’s time.
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Predictive utilisation and associated costs of bevacuzimab with 
chemotherapy in advanced NSCLC
Noonan, Anne M.; Dempsey, Karen; Murray, Michael R.; Priggs,  
Margaret M.; Grogan, Liam; Breathnach, Oscar S. 
Beaumont Hospital / Cancer Centre, Dublin, Ireland
Background: The cost of systemic cancer therapies continues to 
increase and is a major concern to those funding these therapies. Novel 
therapeutics continue to show additional beneﬁt when combined with 
systemic therapies. Our aim was to assess the potential cost impact 
of adding bevacizumab to chemotherapy as per the eligibility criteria 
of the ECOG E4599 trial (Carboplatin, Paclitaxel & Bevacizumab; 
Sandler et al NEJM 2006; 355; 2542-50).
Methods: All patients with NSCLC seen in the clinic of one medical 
oncologist over a 1 year period were assessed. Patients with stage IIIB 
(with malignant pleural effusion), stage IV or recurrent NSCLC were 
selected for consideration. Patients’ records were assessed for inclu-
sion/exclusion criteria as per E4599. Costings for bevacizumab were as 
per epocrates.com quotations ($646 per 100mg).
Results: 49 of 87 patients were eligible for assessment. The male to 
female ratio was 2.5:1. Only 6% (3) of patients were eligible for the 
protocol with bevacizumab. Most patients had at least one of the 12 
exclusion criteria or failed to meet all of the 6 inclusion criteria. The 
top 5 most common exclusion criteria are shown in table 1. 
Exclusion Criteria Patient Numbers (%)
Squamous NSCLC 23 (47%)
NSAIDs / Antiplatelet therapy 14 (29%)
Radiotherapy within 21 days 11 (22%)
Clinically signiﬁcantly cardiovasculr disease 7 (14%)
CNS metastases 6 (12%)
28.5% of patients had an ECOG performance status of >1 and therefore 
failed to meet this inclusion criterion. 
Conclusion: The vast majority of patients with advanced NSCLC 
would not have been eligible for the addition of bevacizumab to 
chemotherapy. With only 6% of patients eligible, the anticipated direct 
drug cost for inclusion of bevacizumab into standard care was lower 
than expected. For an average 70kg male the addition of bevacizumab 
15mg/kg to 6 cycles of chemotherapy would cost an extra $40,698 
and for an average 55kg female the cost is $31,977. If an additional 5 
cycles of bevacizumab monotherapy are given (average until disease 
progression in E4599) the additional costs would be another $33,915 
for males and $26,647 for females. Judicious use of bevacizumab in 
advanced NSCLC shows a doubling in survival at 2 years (from 8 to 
15%) in this highly selected group as per E4599. The additional cost is 
acceptable in this limited population.
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The role of the nurse practitioner thorax oncology in the 
Netherlands
Olijve, Albert; Burgers, Jacobus A. 
Netherlands Cancer Institute, Amsterdam, The Netherlands
Background: The nurse practitioner is a specialized nurse. In his 
professional approach he is able to take over some roles from the 
specialist. He integrates nursing care and medical care. In the 1960s 
